Get the Stockscreener App
0.00
100.00%
-0.0871
After Hours:
.06
0.06
+
Bio Path Holdings Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.0871
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-11.18M
P/E Ratio:
0.00
EPS:
-1.5489
Net Cash Flow:
$-4.48M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-97.18%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.12
Bio Path Holdings Inc Stock (BPTH) Company Profile
Compare BPTH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.00 | 0 | 0 | -11.18M | -4.48M | -1.5489 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-21 | Initiated | ROTH Capital | Buy |
| Nov-13-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Apr-18-16 | Initiated | Rodman & Renshaw | Buy |
| Jun-02-14 | Resumed | Maxim Group | Buy |
| May-09-14 | Initiated | Maxim Group | Buy |
View All
Bio Path Holdings Inc Stock (BPTH) Latest News
In-Depth Examination of Segments, Industry Trends, and Key - openPR.com
Microbot Medical Inc. (MBOT) stock price, news, quote and history - Yahoo Finance Australia
Stock List: Research Stocks from Around the World - GuruFocus
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Analyzing Bio-Path (BPTH) and Its Rivals - defenseworld.net
IXICO Taps Tech Bio Path with Strategic Medidata Deal - kalkinemedia.com
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
[1-A] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Shows Potential with Active Contributions from 70+ Key Companies | DelveInsight - Barchart.com
Bio-Path Holdings, Inc. Announces Domestication to Wyoming and Amendment Creating Series S Preferred Stock - Minichart
Bio-Path Holdings approves Wyoming move and creates new preferred stock class - Investing.com Australia
[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event - Stock Titan
Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX) - Defense World
SEC Filings for Mar 19, 202610-K, 10-Q, 8-K Forms - Stock Titan
Bio-Path (BPTH) to Release Earnings on Friday - Defense World
T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ - openPR.com
Is Bio Path Holdings Inc. (IBP0) stock a defensive play amid uncertaintyQuarterly Trade Review & Long Hold Capital Preservation Plans - Naître et grandir
[1-Z] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split By Investing.com - Investing.com South Africa
Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split - Investing.com Australia
Bio-Path (BPTH) grants CEO affiliate new preferred shares and weighs trial restarts - Stock Titan
BPTHBio-Path Hldgs Inc Latest Stock News & Market Updates - Stock Titan
Head-To-Head Comparison: eFFECTOR Therapeutics (NASDAQ:EFTR) & Bio-Path (NASDAQ:BPTH) - Defense World
Can Bio Path Holdings Inc. (IBP0) stock surprise markets with earningsRate Cut & AI Optimized Trade Strategies - mfd.ru
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease - Yahoo Finance
Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working In The Domain Delveinsight - Mena FN
Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com
Acute Myeloid Leukemia Market Forecast to 2034: 7MM - openPR.com
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer - Yahoo Finance
Antisense Oligonucleotide Therapeutics Clinical Trial - openPR.com
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Bio-Path Holdings Q3 2025: Loss of $976K, Shares at $0.07News and Statistics - IndexBox
Bio-Path: Third Quarter Financial Highlights - Bitget
Bio-Path: Q3 Earnings Snapshot - Barchart.com
BPTH: Operational pause, depleted cash, and debt defaults highlight urgent need for new funding - TradingView
BIO-PATH HOLDINGS, INC. SEC 10-Q Report - TradingView
North American Morning Briefing : Dow Futures Stall Ahead of Key Data -2- - marketscreener.com
Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Is Breakeven Near? - Sahm
Top News Today: Stocks Mixed as Energy Rises, Tech Falls - 富途牛牛
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Gains Momentum: 25+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
North American Morning Briefing : Stock Futures Rise as 2026 Trading Year Begins - MarketScreener
Mondego Bio selects ZE00-0388 as clinical candidate - BioWorld MedTech
What analyst consensus implies for Bio Path Holdings Inc. (IBP0) stockJuly 2025 Rallies & Daily Profit Focused Stock Screening - Улправда
Why analysts recommend Bio Path Holdings Inc. (IBP0) stock2025 Short Interest & Weekly Breakout Watchlists - Улправда
North American Morning Briefing : Stock Futures Up as Investors Bet on Fed Rate Cuts -2- - marketscreener.com
North American Morning Briefing : Dow Futures Climb, Nasdaq Futures Fall -2- - marketscreener.com
Armistice Capital LLC Trims Holdings in UiPath, Inc. $PATH - Defense World
Bio Path Holdings Inc Stock (BPTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
3.83%
Cap:
|
Volume (24h):